Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the NLRP3 inflammasome in inflammatory diseases
Matthew Mangan, Edward J. Olhava, William Roush, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 8, pp. 588-606
Closed Access | Times Cited: 1526

Showing 1-25 of 1526 citing articles:

The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Karen V. Swanson, Meng Deng, Jenny P.‐Y. Ting
Nature reviews. Immunology (2019) Vol. 19, Iss. 8, pp. 477-489
Open Access | Times Cited: 3515
Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study
Hui Yu, Liangbin Lin, Zhiqiang Zhang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1320
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Tao Gong, Lei Liu, Wei Jiang, et al.
Nature reviews. Immunology (2019) Vol. 20, Iss. 2, pp. 95-112
Closed Access | Times Cited: 1288
Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
Yang Yang, Huanan Wang, Mohammed Kouadir, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 2
Open Access | Times Cited: 1053
Caspases in Cell Death, Inflammation, and Disease
Nina Van Opdenbosch, Mohamed Lamkanfi
Immunity (2019) Vol. 50, Iss. 6, pp. 1352-1364
Open Access | Times Cited: 972
Emerging concepts in the science of vaccine adjuvants
Bali Pulendran, Prabhu S. Arunachalam, Derek T. O’Hagan
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 6, pp. 454-475
Open Access | Times Cited: 967
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Oliver Soehnlein, Peter Libby
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 8, pp. 589-610
Open Access | Times Cited: 723
Caspases in Cell Death, Inflammation, and Pyroptosis
Sannula Kesavardhana, R. K. Subbarao Malireddi, Thirumala‐Devi Kanneganti
Annual Review of Immunology (2020) Vol. 38, Iss. 1, pp. 567-595
Open Access | Times Cited: 698
Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome
Humayun Sharif, Li Wang, Wei Li Wang, et al.
Nature (2019) Vol. 570, Iss. 7761, pp. 338-343
Open Access | Times Cited: 620
Inflammasomes in neuroinflammatory and neurodegenerative diseases
Sofie Voet, Sahana Srinivasan, Mohamed Lamkanfi, et al.
EMBO Molecular Medicine (2019) Vol. 11, Iss. 6
Open Access | Times Cited: 604
Pharmacological Inhibitors of the NLRP3 Inflammasome
Ayesha Zahid, Bofeng Li, Arnaud John Kombe Kombe, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 558
Diverging inflammasome signals in tumorigenesis and potential targeting
Rajendra Karki, Thirumala‐Devi Kanneganti
Nature reviews. Cancer (2019) Vol. 19, Iss. 4, pp. 197-214
Open Access | Times Cited: 537
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Kai Li, Houhui Shi, Benxia Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 514
Inflammation and aging: signaling pathways and intervention therapies
Xia Li, Chentao Li, Wanying Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 486
Gout
Nicola Dalbeth, Hyon K. Choi, Leo A. B. Joosten, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 477
NLRP3 and pyroptosis blockers for treating inflammatory diseases
Rebecca C. Coll, Kate Schroder, Pablo Pelegrı́n
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 8, pp. 653-668
Open Access | Times Cited: 425
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
Alexander Hooftman, Stefano Angiari, Svenja Hester, et al.
Cell Metabolism (2020) Vol. 32, Iss. 3, pp. 468-478.e7
Open Access | Times Cited: 420
SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation
Pan Pan, Miaomiao Shen, Zhenyang Yu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 411
NF-κB: At the Borders of Autoimmunity and Inflammation
Laura Barnabei, Emmanuel Laplantine, William Mbongo, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 402
Innate immunity in diabetic kidney disease
Sydney C.W. Tang, Wai Han Yiu
Nature Reviews Nephrology (2020) Vol. 16, Iss. 4, pp. 206-222
Closed Access | Times Cited: 399
Targeting the NLRP3 Inflammasome in Severe COVID-19
Tracey Freeman, Talia H. Swartz
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 389
Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling
Hongxu Xian, Kosuke Watari, Elsa Sánchez‐López, et al.
Immunity (2022) Vol. 55, Iss. 8, pp. 1370-1385.e8
Open Access | Times Cited: 380
Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases
Matthew Mangan, Edward J. Olhava, William Roush, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 9, pp. 688-688
Open Access | Times Cited: 362
NLRP3 inflammasome in endothelial dysfunction
Baochen Bai, Yanyan Yang, Qi Wang, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 9
Open Access | Times Cited: 349
Pyroptosis in inflammatory diseases and cancer
Zhiping Rao, Yutong Zhu, Peng Yang, et al.
Theranostics (2022) Vol. 12, Iss. 9, pp. 4310-4329
Open Access | Times Cited: 344
Page 1 - Next Page

Scroll to top